Icatibant Generics (Uk)

Icatibant, the active ingredient in Icatibant Generics (Uk), is a Bradykinin B2 receptor antagonist presented as a solution for injection for subcutaneous use. It treats acute attacks of hereditary angioedema type I and type II in patients who experience rapid swelling of the skin, gastrointestinal tract, or airway.

GNH USA supplies Icatibant Generics (Uk) as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance to meet global demand.

Icatibant is used to treat hereditary angioedema by targeting the bradykinin pathway. - Hereditary angioedema type I: provides rapid reduction of swelling and pain during acute attacks. - Hereditary angioedema type II: delivers swift control of edema and associated discomfort in acute episodes. - Bradykinin‑mediated angioedema: alleviates symptoms by blocking bradykinin effects that cause vascular leakage.

Icatibant may cause a range of adverse reactions, most of which are related to its injection route or pharmacologic activity.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness at injection site: localized erythema. - Swelling at injection site: transient edema. - Nausea: occasional feeling of queasiness. - Headache: mild to moderate head pain. - Dizziness: brief sensation of light‑headedness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Severe hypotension: marked drop in blood pressure. - Angioedema paradoxical: unexpected swelling despite treatment. - Urticaria: widespread hives. - Thrombocytopenia: low platelet count. - Severe injection site reaction: necrosis or infection.

When using Icatibant, several safety considerations should be observed to minimize risk. - Pregnancy: safety not established; avoid unless clearly needed. - Breastfeeding: unknown safety; weigh benefits against potential risks. - Renal impairment: use with caution; monitor renal function. - Concomitant ACE inhibitors: may increase bradykinin levels; observe for enhanced edema. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medicines that influence the bradykinin system or cardiovascular function.

Major Interactions (Avoid): - ACE inhibitors: may raise bradykinin levels and increase risk of angioedema. - Angiotensin receptor blockers: similar potential to augment bradykinin‑mediated effects.

Moderate Interactions (Monitor Closely): - Diuretics: monitor blood pressure and electrolyte balance. - Other bradykinin antagonists: additive pharmacologic effect may require dose adjustment. - NSAIDs: may affect edema control and renal function.